Opinion https://www.benzinga.com/views/taxonomy/term/146540 en Thinking about buying stock in Aurora Cannabis, California Resources, McDermott International, Micron Technology, or Uber Technologies? https://www.benzinga.com/pressreleases/19/09/n14464505/thinking-about-buying-stock-in-aurora-cannabis-california-resources-mcdermott-international-micron <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 20, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, CRC, MDR, MU, and UBER.</p> <p xmlns="http://www.w3.org/1999/xhtml">To see how InvestorsObserver&#39;s proprietary scoring system rates these stocks, view the InvestorsObserver&#39;s PriceWatch Alert by selecting the corresponding link.</p> <ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml">ACB: <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/19/09/n14464505/thinking-about-buying-stock-in-aurora-cannabis-california-resources-mcdermott-international-micron alt=Thinking about buying stock in Aurora Cannabis, California Resources, McDermott International, Micron Technology, or Uber Technologies?>Full story available on Benzinga.com</a></p> ACB Banking/Financial Services CRC MDR MU UBER Opinion Press Releases CRC US1711171041 MDR PA5800371096 MU US5951121038 UBER ACB Opinion Press Releases Benzinga Fri, 20 Sep 2019 13:31:00 +0000 PRNewswire 14464505 at https://www.benzinga.com Thinking about trading options or stock in Alphabet, JPMorgan Chase, Netflix, NVIDIA, or Tesla? https://www.benzinga.com/pressreleases/19/09/n14464506/thinking-about-trading-options-or-stock-in-alphabet-jpmorgan-chase-netflix-nvidia-or-tesla <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 20, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOOGL, JPM, NFLX, NVDA, and TSLA.</p> <p xmlns="http://www.w3.org/1999/xhtml">Click a link below then choose between in-depth options trade idea report or a stock score report.</p> <p xmlns="http://www.w3.org/1999/xhtml">Options Report – Ideal trade ideas on up to seven different options ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14464506/thinking-about-trading-options-or-stock-in-alphabet-jpmorgan-chase-netflix-nvidia-or-tesla alt=Thinking about trading options or stock in Alphabet, JPMorgan Chase, Netflix, NVIDIA, or Tesla?>Full story available on Benzinga.com</a></p> Banking/Financial Services GOOGL JPM NFLX NVDA TSLA Opinion Press Releases NFLX US64110L1061 NVDA US67066G1040 JPM US46625H1005 TSLA US88160R1014 GOOGL US38259P5089 Opinion Press Releases Benzinga Fri, 20 Sep 2019 13:31:00 +0000 PRNewswire 14464506 at https://www.benzinga.com Financialbuzz.com: 'Market Recap' Week Ending September 20th, 2019 https://www.benzinga.com/pressreleases/19/09/n14464233/financialbuzz-com-market-recap-week-ending-september-20th-2019 <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 20, 2019</span> /PRNewswire/ --  U.S. markets opened lower on Monday following the attacks on Saudi Arabian oil facilities. On Sunday, crude oil prices surged by more than 10% after drone attacks targeted two major Saudi Aramco oil facilities. The attacks decimated more than half of the crude output from the world&#39;s largest exporter, affecting 5 million barrels of daily crude oil production. The Dow Jones Industrial Average declined by as much as 150 points on Monday from Friday&#39;s closing bell. Despite the attacks, Saudi Arabian Energy Minister Prince <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Abdulaziz bin Salman</span> said on Tuesday that the country&#39;s oil supply levels were back to the same levels prior to the attack. Bin Salman also noted that the country&#39;s oil market will be fully back online by the end of September. On Tuesday, markets continued to edge lower ahead of the Federal Reserve&#39;s two-day meeting regarding interest rates. On Wednesday, markets opened higher after the Federal Reserve trimmed its benchmark interest rate to 1.75% from 2%, marking the second rate cut in the past months amid U.S.-<span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">China</span> trade war tensions. Throughout Wednesday, the Dow declined by as much as 120 points following the Federal Reserve&#39;s decision. Shortly after, U.S. President <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Donald Trump</span> expressed his displeasure about the quarter rate cut. Trump mentioned earlier in the week that he wanted the Feds to cut interest rates to &#34;zero or less.&#34; Additionally, on Thursday, Trump told Treasury Secretary <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Steven Mnuchin</span> to &#34;substantially increase&#34; sanctions on <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Iran</span> following the attacks on the oil facilities. On Thursday, stocks edged higher by 100 points shortly after the opening bell as investors digested the Federal Reserve rate cut. Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ" rel="nofollow">ADBE</a>), FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE" rel="nofollow">FDX</a>), Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE" rel="nofollow">CHWY</a>), General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE" rel="nofollow">GIS</a>), Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ" rel="nofollow">DDOG</a>) </p> <p xmlns="http://www.w3.org/1999/xhtml">The Federal Reserve&#39;s decision to slash interest rates by a quarter percentage in an effort to prevent a slowdown in the global economic growth and hinder the possible impacts of Trump&#39;s trade policies. However, the U.S. and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">China</span> resumed trade talks on Thursday, as officials from both nations met for the first time in nearly two months. The negotiations on Thursday and Friday are expected to layout a groundwork for high-level talks in October that will address the matter whether the two are able to reach a common agreement or result in additional tariffs. &#34;The majority of market participants are still digesting the Fed, and we saw a quick shift of the focus back to the trade war,&#34; said <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Edward Moya</span>, Senior Market Analyst at OANDA. &#34;Markets thought this was supposed to be an easy week for trade,&#34; Moya told MarketWatch, but instead, the South China Morning Post reported that a senior White House official said tariffs on Chinese goods could go as high as 50 or even 100%.</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Adobe Inc.</b> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ" rel="nofollow">ADBE</a>) reported its third quarter financial results after the market close on Tuesday. Despite beating expectations, Adobe shares edged lower by 4% at the opening bell on Wednesday. For the fourth quarter, Adobe reported earnings of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 2.05</span> per share on revenue of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 2.83 Billion</span>. Analysts expected earnings of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 1.97</span> per share on revenues of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 2.82 Billion</span>. However, the Company provided a weaker-than-expected guidance for the fourth quarter. Adobe is anticipating earnings of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 2.25</span> ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14464233/financialbuzz-com-market-recap-week-ending-september-20th-2019 alt=Financialbuzz.com: &#039;Market Recap&#039; Week Ending September 20th, 2019>Full story available on Benzinga.com</a></p> ADBE CHWY DDOG FDX GIS Oil Utilities Commodities Small Cap Opinion Press Releases ADBE US00724F1012 FDX US31428X1063 GIS US3703341046 CHWY DDOG Commodities Small Cap Opinion Press Releases Benzinga Fri, 20 Sep 2019 13:00:00 +0000 PRNewswire 14464233 at https://www.benzinga.com Positive Trial Results Help to Spur Cannabis Legalization Efforts Worldwide https://www.benzinga.com/pressreleases/19/09/n14464267/positive-trial-results-help-to-spur-cannabis-legalization-efforts-worldwide <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 20, 2019</span> /PRNewswire/ -- The U.S. Drug Enforcement Agency recently announced plans to expand cannabis research after a prolonged delay. The DEA said it hopes to receive a variety of compelling research about marijuana after the agency delisted CBD, or cannabidiol, from the Schedule 1 list last year.It is important to note, however, that the cannabis plant itself is still a Schedule 1 drug. CBD, meanwhile, is a compound found within the hemp plant, which falls within the cannabis family. Previously, cannabis research was heavily limited as there were only few researchers who were allowed to cultivate and provide cannabis for medical purposes. However, over the past several years, many researchers have delivered uplifting results from clinical trials that proved cannabis is a reliable and effective medical treatment. Now, medical cannabis is predominantly being used to alleviate symptoms associated with afflictions such as chronic pain, cancer, and epilepsy. The positive data has even led many U.S. states to legalize medical cannabis. And as of 2019, there were 33 states and the <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">District of Columbia</span> that have already moved to legalize medical cannabis. In general, the U.S. was one of the earliest adopters of medical cannabis when <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span> first legalized medical use in 1996. Since then, a number of countries such as <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Australia</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Colombia</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Germany</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">France</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Spain</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Thailand</span>, and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">South Korea</span> have all been influenced by the remarkable data and have also moved to legalize medical cannabis. As a result, the global legal marijuana market is expected to reach <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 146.4 Billion</span> by 2025 while registering a CAGR of 34.6%, according to data compiled by Grand View Research. Pasha Brands Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRFTF#OTC" rel="nofollow">CRFTF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CRFT#CSE" rel="nofollow">CRFT</a>), Tilray, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ" rel="nofollow">TLRY</a>), Cronos Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ" rel="nofollow">CRON</a>), Aurora Cannabis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NYSE" rel="nofollow">ACB</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX" rel="nofollow">ACB</a>), The Green Organic Dutchman Holdings Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGODF#OTC" rel="nofollow">TGODF</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TGOD#TSX" rel="nofollow">TGOD</a>) </p> <p xmlns="http://www.w3.org/1999/xhtml">While most regions are legalizing cannabis primarily for medical purposes, a number of countries have also decided to either decriminalize or legalize recreational use as well. Specifically, some countries are looking to legalize recreational use for the economic benefits as well as a means to end the war on drugs in high profile regions. In particular, countries such as <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Mexico</span>, the U.S., and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">New Zealand</span> are potentially likely candidates to implement  nation-wide legislation in the coming future. Nonetheless, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Canada</span> and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Uruguay</span> are the only two countries that have fully legalized cannabis as of now. However, in an economic perspective, it was speculated that Americans spent roughly between <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 8.6 Billion</span> and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 10 Billion</span> on legal marijuana in 2018, according to Marijuana Business Daily. And while the sales of cannabis are helping boost the overall industry, they also help drive bolster the economies of the states where the plant is legally sold. For instance, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Washington</span> has implemented a 37% sales tax on legal recreational cannabis, while <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span> has implemented a 15% sales tax, while cultivators also pay a product tax per ounce. Notably, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Washington</span> collected the most taxes last year with an estimated <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 319 Million</span> while <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span> came in second with an estimated <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 300 Million</span> in cannabis tax revenue, according to <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Niall McCarthy</span>, Senior Data Journalist at Statista. Leafly said that the tax revenue is being used by states to support jobs in school, construction, drug abuse programs, and medical research. Moreover, the acceleration of the legal cannabis market created 300,000 jobs last year, bolstering the economy with higher tax revenues. &#34;One of the biggest pro-legalization arguments was that states would be able to bring in a new source of tax revenue,&#34; said <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Liberty Vittert</span>, Professor of Practice in Data Analytics at <span xmlns="http://www.w3.org/1999/xhtml" class="xn-org">Washington University</span>. &#34;While there are still many unknowns surrounding the legalization of recreational marijuana, I believe that this shows that it will be a positive influence.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Pasha Brands Ltd.</b> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRFTF#OTC" rel="nofollow">CRFTF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CRFT#CSE" rel="nofollow">CRFT</a>) is also listed on the Canadian Securities Exchange under the ticker (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CRFT#CSE" rel="nofollow">CRFT</a>). Yesterday, the Company announced that, &#34;its wholly owned subsidiary, BC Craft Supply Co. Ltd (&#34;BC Craft&#34;), has signed over 100 micro-cultivator applicants (&#34;Micros&#34;) across <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Canada</span> to date.</p> <p xmlns="http://www.w3.org/1999/xhtml">Once licensed, a Micro can produce approximately 500 kilograms of dried flower per year in the 2150 sq ft legally allowed. With these supply deals in place, including the first three Micros licensed by Health Canada, Pasha anticipates being able to bring an excess of 50,000 kilograms of craft cannabis per year to market as more licences are issued. This would make Pasha one of the largest craft cannabis providers in the world.</p> <p xmlns="http://www.w3.org/1999/xhtml">Tens of thousands of grey market cannabis producers coast to coast still supply as much as 85% of the cannabis Canadians are consuming. Issues with quality, freshness, and availability have plagued legalization so far as industrial cannabis producers strive to grow mass quantities of cannabis. Prices for limited supplies of small batch craft cannabis flower, sold through online Provincial cannabis retailers are now exceeding <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$20</span> per gram, and little has been done to address the impact on ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14464267/positive-trial-results-help-to-spur-cannabis-legalization-efforts-worldwide alt=Positive Trial Results Help to Spur Cannabis Legalization Efforts Worldwide>Full story available on Benzinga.com</a></p> ACB CRFTF CRON CSE:CRFT TGODF TLRY TSX:ACB TSX:TGOD Opinion Press Releases ACB TSX:ACB CRON TSX:TGOD TGODF TLRY US88688T1007 CSE:CRFT CRFTF Opinion Press Releases Benzinga Fri, 20 Sep 2019 13:00:00 +0000 PRNewswire 14464267 at https://www.benzinga.com Thinking about trading options or stock in Blackstone, FedEx, Goldman Sachs, Intel, or Roku? https://www.benzinga.com/pressreleases/19/09/n14458357/thinking-about-trading-options-or-stock-in-blackstone-fedex-goldman-sachs-intel-or-roku <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 19, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BX, FDX, GS, INTC, and ROKU.</p> <p xmlns="http://www.w3.org/1999/xhtml">Click a link below then choose between in-depth options trade idea report or a stock score report.</p> <p xmlns="http://www.w3.org/1999/xhtml">Options Report – Ideal trade ideas on up to seven different options trading ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14458357/thinking-about-trading-options-or-stock-in-blackstone-fedex-goldman-sachs-intel-or-roku alt=Thinking about trading options or stock in Blackstone, FedEx, Goldman Sachs, Intel, or Roku?>Full story available on Benzinga.com</a></p> Banking/Financial Services BX FDX GS INTC ROKU Opinion Press Releases INTC US4581401001 BX US09253U1088 FDX US31428X1063 GS US38141G1040 ROKU Opinion Press Releases Benzinga Thu, 19 Sep 2019 13:31:00 +0000 PRNewswire 14458357 at https://www.benzinga.com Thinking about buying stock in AIM ImmunoTech, Beyond Meat, Walt Disney Co, Microsoft, or SPI Energy? https://www.benzinga.com/pressreleases/19/09/n14458358/thinking-about-buying-stock-in-aim-immunotech-beyond-meat-walt-disney-co-microsoft-or-spi-energy <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 19, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AIM, BYND, DIS, MSFT, and SPI.</p> <p xmlns="http://www.w3.org/1999/xhtml">To see how InvestorsObserver&#39;s proprietary scoring system rates these stocks, view the InvestorsObserver&#39;s PriceWatch Alert by selecting the corresponding link.</p> <ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml">AIM: <a xmlns="http://www.w3.org/1999/xhtml" ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/19/09/n14458358/thinking-about-buying-stock-in-aim-immunotech-beyond-meat-walt-disney-co-microsoft-or-spi-energy alt=Thinking about buying stock in AIM ImmunoTech, Beyond Meat, Walt Disney Co, Microsoft, or SPI Energy?>Full story available on Benzinga.com</a></p> AIM Banking/Financial Services BYND DIS MSFT SPI Opinion Press Releases AIM US0080153077 SPI MSFT US5949181045 DIS US2546871060 BYND Opinion Press Releases Benzinga Thu, 19 Sep 2019 13:31:00 +0000 PRNewswire 14458358 at https://www.benzinga.com Daiki Axis' Business Strategies and Earnings Reviewed by KCR https://www.benzinga.com/pressreleases/19/09/n14458318/daiki-axis-business-strategies-and-earnings-reviewed-by-kcr <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">TOKYO</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 19, 2019</span> /PRNewswire/ -- </p> <p xmlns="http://www.w3.org/1999/xhtml"><a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="http://www.daiki-axis.com/english/" rel="nofollow" rel="nofollow">Daiki Axis Co., Ltd. (TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:4245#TYO" rel="nofollow">4245</a>) </a>, an eco-creation and development company that creates social infrastructure centered on water-related businesses, recently has been reviewed by KCR Inc., an independent research and investor relations support company providing reports on various publicly traded Japanese companies. In this report, KCR provides analysis of the company&#39;s business model and earnings.</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Report Highlights</b></p> <p xmlns="http://www.w3.org/1999/xhtml">Daiki Axis Co., Ltd. (4245, First Section, Tokyo Stock Exchange) promotes its corporate slogan, &#34;Protect and change&#34; (Protect the global environment and change humanity&#39;s future) as its business mission. The Company is developing its businesses, including its key water businesses, aiming to become an eco-creation and development company that constructs social infrastructure that provides natural and comfortable living environments for people.</p> <p xmlns="http://www.w3.org/1999/xhtml">Daiki Axis is promoting ESG management by pushing forward with initiatives aimed at increasing its use of renewable energy to 100% (Environment) , advancing diversity by encouraging work-style reforms and the active participation of women in the workforce (Society) and reforming its managerial structure while strengthening risk management (Governance).</p> <p xmlns="http://www.w3.org/1999/xhtml">The Company formulated a new medium-term management plan, &#34;Make FOUNDATION Plan.&#34; This plan sets new targets for the period from 2019 to 2021. For the fiscal year ending <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">December 31, 2021</span>, the Company forecasts net sales of \40,000 million, ordinary income of \1,800 million and profit attributable to owners of parent of \1,100 million. While focusing on raising profitability, the Company is also targeting ROE of 13.2% or more and ROIC of 5.5% or higher. The current Company policy is to cover investment, which will take priority for the time being, with owned capital and bank loans.</p> <p xmlns="http://www.w3.org/1999/xhtml">During the six months ended <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">June 30, 2019</span>, the Company generated net sales of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">JPY17,848 million</span> (up 2.4% YoY), ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14458318/daiki-axis-business-strategies-and-earnings-reviewed-by-kcr alt=Daiki Axis&#039; Business Strategies and Earnings Reviewed by KCR>Full story available on Benzinga.com</a></p> Banking/Financial Services Environmental Products & Services TYO:4245 Utilities Water Utilities Commodities Opinion Press Releases TYO:4245 Commodities Opinion Press Releases Benzinga Thu, 19 Sep 2019 13:30:00 +0000 PRNewswire 14458318 at https://www.benzinga.com Small Scale Cannabis Growers Carve Out a Niche in the Burgeoning Industry https://www.benzinga.com/pressreleases/19/09/n14458015/small-scale-cannabis-growers-carve-out-a-niche-in-the-burgeoning-industry <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 19, 2019</span> /PRNewswire/ -- As the cannabis industry continues to advance, competition among operators is becoming more and more fierce. In particular, the competition between growers has become much more prevalent when compared to retailers, according to <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Deepak Anand</span>, a cannabis industry expert based in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Vancouver</span>. As of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">March 2019</span>, statistics released by Health Canada indicated that the agency only received 150 applications for micro-cultivation or processing licenses. Generally, macro-cultivators tend to dominate the cultivation segment of the overall cannabis industry, as they are able to produce tons of cannabis each harvest. By mass-producing cannabis, macro-cultivators can wholesale their supply to distributors and retailers at a cheaper price. However, Anand noted that micro-cultivators have to wait for at least 18-months before getting approved for a license, which usually deters entrepreneurs from applying. As a result, many micro-cultivators find themselves working in gray markets while waiting for approvals. Nonetheless, numerous service providers within the industry have secured partnerships and contracts with companies awaiting such license approvals. For instance, companies have hired consultants to guide them throughout the process of receiving an approval. Moreover, some producers have inked agreements with companies to supply them with their own products in an effort to accelerate their approval time. Furthermore, according to data compiled by GlobalInfoResearch, the global legal marijuana market was valued at <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 7.97 Billion</span> in 2019. And by 2024, it is expected to reach <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 35 Billion</span> while registering a CAGR of 28% over the next five years. Pasha Brands Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRFTF#OTC" rel="nofollow">CRFTF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CRFT#CSE" rel="nofollow">CRFT</a>), Innovative Industrial Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE" rel="nofollow">IIPR</a>), Aphria Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APHA#NYSE" rel="nofollow">APHA</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/APHA#TSX" rel="nofollow">APHA</a>), HEXO Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEXO#NYSE" rel="nofollow">HEXO</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HEXO#TSX" rel="nofollow">HEXO</a>), Green Thumb Industries Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC" rel="nofollow">GTBIF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GTII#CSE" rel="nofollow">GTII</a>)</p> <p xmlns="http://www.w3.org/1999/xhtml">In 2017, Health Canada announced its intent to issue more licenses for micro-cultivators in hopes to &#34;enable a diverse, competitive legal industry comprised of both large and small players in regions across the country.&#34; However, in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">January 2019</span>, there were only 145 authorized cultivators in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Canada</span>. Moreover, there were approximately 840 site applications in process at the end of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">December 2018</span>, Health Canada told Marijuana Business Daily. Nonetheless, approved micro-cultivators are already moving towards redefining the cannabis industry. Typically, micro-cultivators are limited to only 200 square meters of space, which can sustain anywhere from one to eight plants per square meter. The yield per plant can heavily vary depending on environmental factors such as the lighting, airflow, humidity, and spacing between the plants. Most importantly, the yield can be substantially increased by hand-trimming plants instead of using machinery. Notably, micro-cultivators, specifically &#34;craft cannabis cultivators,&#34; boast about their high quality and organic growing process that produces premium cannabis. Specifically, craft cultivators strive to provide their consumers with all natural and potent products that stand out against competitors. Normally, craft producers avoid using artificial products such as pesticides to appeal to health conscious consumers. However, as a result of avoiding the use of pesticides, craft producers are required to manually tend to each and every individual plant to ensure a healthy growing process. While it may seem tedious to tend to each plant, it allows cultivators to create premium cannabis strains by carefully monitoring each growing phase. And then when it&#39;s time to harvest, craft producers hand-trim every plant in order to preserve and maintain the cannabinoid integrity throughout the harvest. &#34;Nearly every marijuana cultivator wants to call its cannabis craft. Whether the plant is grown indoors or outside, with a hydroponic irrigation system or a watering can, under the sun or high-tech LED lights, few growers want their flower to be considered corporate cannabis,&#34; said <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Bart Schaneman</span>, Cultivation and Extraction Reporter at Marijuana Business Daily. &#34;As a general philosophy, a cannabis grower looking to brand its flower as craft needs to show the consumer that the flower was grown with mindfulness and close attention paid to each plant.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Pasha Brands Ltd.</b> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRFTF#OTC" rel="nofollow">CRFTF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CRFT#CSE" rel="nofollow">CRFT</a>) is also listed on the Canadian Securities Exchange under the ticker (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CRFT#CSE" rel="nofollow">CRFT</a>). Just announced breaking cannabis news, &#34;<span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">North America&#39;s</span> largest craft cannabis brand house, is delighted to announce that its wholly owned subsidiary, BC Craft Supply Co. Ltd (&#34;BC Craft&#34;), has signed over 100 micro-cultivator applicants (&#34;Micros&#34;) across <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Canada</span> to date.</p> <p xmlns="http://www.w3.org/1999/xhtml">Once licensed, a Micro can produce approximately 500 kilograms of dried flower per year in the 2150 sq ft legally allowed. With these supply deals in place, including the first three Micros licensed by Health Canada, Pasha anticipates being able to bring an excess of 50,000 kilograms of craft cannabis per year to market as more licences are issued. This would make Pasha one of the largest craft cannabis providers in the world.</p> <p xmlns="http://www.w3.org/1999/xhtml">Tens of thousands of grey market cannabis producers coast to coast still supply as much as 85% of the cannabis Canadians are consuming. Issues with quality, freshness, and availability have plagued legalization so far as industrial cannabis producers strive to grow mass quantities of ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14458015/small-scale-cannabis-growers-carve-out-a-niche-in-the-burgeoning-industry alt=Small Scale Cannabis Growers Carve Out a Niche in the Burgeoning Industry>Full story available on Benzinga.com</a></p> APHA CRFTF CSE:CRFT CSE:GTII GTBIF HEXO IIPR TSX:APHA TSX:HEXO Small Cap Opinion Press Releases IIPR TSX:HEXO GTBIF APHA TSX:APHA HEXO CSE:GTII CSE:CRFT CRFTF Small Cap Opinion Press Releases Benzinga Thu, 19 Sep 2019 13:00:00 +0000 PRNewswire 14458015 at https://www.benzinga.com Multiple Reports Agree That Cannabis Market Growth Shows No Signs of Slowing https://www.benzinga.com/pressreleases/19/09/n14457843/multiple-reports-agree-that-cannabis-market-growth-shows-no-signs-of-slowing <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">PALM BEACH, Florida</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 19, 2019</span> /PRNewswire/ -- Recent articles, like <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://www.investopedia.com/biggest-challenges-for-the-cannabis-industry-in-2019-4583874" rel="nofollow" rel="nofollow">one</a> in Investopedia, show that there is no denying that 2018 was a major year for the legal cannabis industry. Last year, legal cannabis broke new ground in many ways. Several U.S. states legalized medical or recreational marijuana, as did <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Canada</span>. The FDA approved the first cannabis-based drug treatments. Companies saw their stocks rise to tremendous new highs and it seemed that the dynamic of the industry changed every day, with fast-paced mergers and acquisitions (M&amp;A), new companies launching and older outfits coming to prominence. Marijuana Business Daily (&#34;MBD&#34;) also <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://mjbizdaily.com/chart-putting-the-55-billion-us-retail-cannabis-market-in-perspective/" rel="nofollow" rel="nofollow">reported</a> data in its Marijuana Business Factbook that shows how quickly the industry has grown, saying: &#34;With revenue of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$5.8 billion</span>-<span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$6.6 billion</span>, sales of legal recreational and medical cannabis in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">the United States</span> in 2017 topped those of Oreos and organic produce combined.&#34; Grandview Research added that the cannabis industry is on a tremendous upswing, with numbers expected to reach <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$31.4 billion</span> by the year 2021. Active cannabis companies in the markets this week include <b xmlns="http://www.w3.org/1999/xhtml">Tilray, Inc. </b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ" rel="nofollow">TLRY</a>), <b xmlns="http://www.w3.org/1999/xhtml">Integrated Cannabis Company, Inc</b>. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ICNAF#OTCQB" rel="nofollow">ICNAF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/ICAN#CSE" rel="nofollow">ICAN</a>), <b xmlns="http://www.w3.org/1999/xhtml">The Supreme Cannabis Company, Inc. </b>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/SPRWF#OTCQX" rel="nofollow">SPRWF</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FIRE#TSX" rel="nofollow">FIRE</a>), <b xmlns="http://www.w3.org/1999/xhtml">Valens GroWorks Corp. </b>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/VGWCF#OTCQX" rel="nofollow">VGWCF</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/VGW#TSXV" rel="nofollow">VGW</a>), <b xmlns="http://www.w3.org/1999/xhtml">The Green Organic Dutchman Holdings Ltd. </b>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TGODF#OTCQX" rel="nofollow">TGODF</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TGOD#TSX" rel="nofollow">TGOD</a>).</p> <p xmlns="http://www.w3.org/1999/xhtml">The MBD article continued: &#34;It now rivals Americans&#39; collective spending on Netflix subscriptions – and will likely surpass McDonald&#39;s annual U.S. revenue now that <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California&#39;s</span> massive new legal industry is getting off the ground. By the end of 2019, sales of legal cannabis in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">the United States</span> could overtake those of firearms and ammunition, an industry with a huge amount of influence on Capitol Hill. Continued growth in mature medical and recreational markets, legalization in new states and further development of recently launched MMJ and rec industries will be the primary drivers of growth for the U.S. marijuana industry over the coming years.</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Integrated Cannabis Company, Inc. </b>(CSE:<a class="ticker" href="https://www.benzinga.com/stock/ICAN#CSE" rel="nofollow">ICAN</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/ICNAF#OTCQB" rel="nofollow">ICNAF</a>) <b xmlns="http://www.w3.org/1999/xhtml">BREAKING NEWS</b>: <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://www.icaninc.com/" rel="nofollow" rel="nofollow">Integrated Cannabis Company</a> a multi-state brand operator in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span> and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Nevada</span>, is pleased to announce that its wholly-owned subsidiary, Ganja Gold, is the top infused pre-roll brand in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span>, through <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">July 2019</span>, with roughly <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD$3,300,000</span> in sales to date for fiscal year 2019. </p> <p xmlns="http://www.w3.org/1999/xhtml">According to BDS Analytics, &#34;This past July, consumers in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span> spent <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$25 million</span> on Pre-Rolled products, a 66 percent increase compared to <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">July 2018</span>. While sales of Flower have ceded share to other categories, Pre-Rolled products are another matter. This past July, revenues from Pre-rolled products contributed nine percent towards overall revenue in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">California</span>.&#34; Furthermore, the number 1 and number 3 selling SKUs in the infused pre-roll category ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14457843/multiple-reports-agree-that-cannabis-market-growth-shows-no-signs-of-slowing alt=Multiple Reports Agree That Cannabis Market Growth Shows No Signs of Slowing>Full story available on Benzinga.com</a></p> CSE:ICAN CSE:TTT ICNAF SPRWF TGODF TLRY TSX:FIRE TSX:TGOD TSXV:VGW TTTSF VGWCF Small Cap Opinion Press Releases SPRWF CA86863P1099 TSX:FIRE TSX:TGOD TGODF TLRY US88688T1007 ICNAF VGWCF CSE:ICAN CSE:TTT TTTSF TSXV:VGW Small Cap Opinion Press Releases Benzinga Thu, 19 Sep 2019 12:55:00 +0000 PRNewswire 14457843 at https://www.benzinga.com Consumer Interest in Cannabis-CBD Infused Products at All Time High https://www.benzinga.com/pressreleases/19/09/n14457606/consumer-interest-in-cannabis-cbd-infused-products-at-all-time-high <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">PALM BEACH, Florida</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 19, 2019</span> /PRNewswire/ -- Consumer demand is a powerful force. It can make or break a product or even an industry but the increasing consumer appetite for Cannabis - CBD infused products are showing that it can even stabilize the market even in the midst of a temporary downturn in the industry. In fact, The Green Fund <a xmlns="http://www.w3.org/1999/xhtml" target="_blank" href="https://thegreenfund.com/the-edibles-extracts-and-concentrates-market" rel="nofollow" rel="nofollow">recently</a> stated: &#34;Although the cannabis industry is currently in the midst of a temporary downturn, public interest in the market has never been greater.&#34; They say that the entry of high-level celebrities has helped raise consumer demand and drawn in many new investors alike. They say: &#34;Celebrities like Snoop Dogg, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Martha Stewart</span> and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Mike Tyson</span> have begun lending their names to cannabis companies and investors are increasingly interested in securing a piece of the market for themselves. And it&#39;s not hard to see why, when a 2019 study conducted by Grand View Research predicted that the legal cannabis market could be worth as much as USD <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$66.3 billion</span> by the end of 2025. However, while most cannabis users have historically gravitated towards smoking — either recreationally or for medicinal purposes — as their preferred way of ingesting the drug, consumer attitudes are beginning to change.  Active cannabis companies in the markets this week include:  <b xmlns="http://www.w3.org/1999/xhtml">Medicine Man Technologies, Inc.</b> (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MDCL#OTCQX" rel="nofollow">MDCL</a>), <b xmlns="http://www.w3.org/1999/xhtml">Aurora Cannabis Inc. </b>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NYSE" rel="nofollow">ACB</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACB#TSX" rel="nofollow">ACB</a>), <b xmlns="http://www.w3.org/1999/xhtml">Curaleaf Holdings, Inc. </b>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTCQX" rel="nofollow">CURLF</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CURA#CSE" rel="nofollow">CURA</a>), <b xmlns="http://www.w3.org/1999/xhtml">CV Sciences, Inc. </b>(OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB" rel="nofollow">CVSI</a>), <b xmlns="http://www.w3.org/1999/xhtml">OrganiGram Holdings Inc. </b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ" rel="nofollow">OGI</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OGI#TSX" rel="nofollow">OGI</a>).</p> <p xmlns="http://www.w3.org/1999/xhtml">The Green Fund article continued: &#34;A huge shift is coming — which some pundits have begun referring to as &#34;Legalization 2.0&#34; — that will see a new wave of cannabis edibles, extracts and concentrates hit the market. Like many industries that are in an embryonic stage of development, the marijuana sector is still figuring out what products will be its future growth drivers. One sector of the industry that&#39;s beginning to take center stage is the Edibles Market — which encompasses CBD-infused foods and beverages — with revenue project to grow to <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">$4.1 billion</span> by 2022, according to a recent study published by ArcView Research.</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Medicine Man Technologies, Inc. </b>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/MDCL#OTCQX" rel="nofollow">MDCL</a>) <b xmlns="http://www.w3.org/1999/xhtml">BREAKING NEWS</b>:  Medicine Man Technologies announced this week a culmination of its roll-up strategy today that would solidify the Company as <b xmlns="http://www.w3.org/1999/xhtml">one of the largest vertically integrated cannabis operators in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">North America</span></b> upon closing of these pending acquisitions—and as a deeply experienced retailer and manufacturer of cannabis-infused products and concentrates driven by a leadership team that has unprecedented experience in regulated cannabis markets.</p> <p xmlns="http://www.w3.org/1999/xhtml">As previously disclosed, the Company — which also includes a new executive team with decades of experience in mergers &amp; acquisitions, private equity, strategic operations and corporate finance—has entered into binding term sheets to acquire some of the best-selling cannabis brands in the legal <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Colorado</span> cannabis industry, a combination of pending transactions that spans 12 cultivation facilities (including Los Sueños Farms LLC, one of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">North America&#39;s</span> largest sustainable cannabis farms); seven proprietary extraction facilities (including Purplebee&#39;s); seven manufacturers of infused products (including Medically Correct, one of <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Colorado&#39;s</span> largest edible manufacturers; licensed producer of incredibles in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Colorado</span>, and creators of new brands Quiq and Nove, set to launch this fall); 33 strategically located retail dispensaries (including five Starbuds-branded dispensaries in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Colorado</span>); and a state-of-the-art manufacturing / research and development lab (MedPharm&#39;s <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Colorado</span> ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14457606/consumer-interest-in-cannabis-cbd-infused-products-at-all-time-high alt=Consumer Interest in Cannabis-CBD Infused Products at All Time High>Full story available on Benzinga.com</a></p> ACB CSE:CURA CURLF CVSI MDCL OGI TSX:ACB TSX:OGI Small Cap Opinion Press Releases CVSI OGI ACB MDCL TSX:OGI TSX:ACB CURLF CSE:CURA Small Cap Opinion Press Releases Benzinga Thu, 19 Sep 2019 12:30:00 +0000 PRNewswire 14457606 at https://www.benzinga.com Thinking about trading options or stock in Apple, Citigroup, Facebook, Coca-Cola, or Merck? https://www.benzinga.com/pressreleases/19/09/n14450889/thinking-about-trading-options-or-stock-in-apple-citigroup-facebook-coca-cola-or-merck <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 18, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, C, FB, KO, and MRK.</p> <p xmlns="http://www.w3.org/1999/xhtml">Click a link below then choose between in-depth options trade idea report or a stock score report.</p> <p xmlns="http://www.w3.org/1999/xhtml">Options Report – Ideal trade ideas on up to seven different options trading ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14450889/thinking-about-trading-options-or-stock-in-apple-citigroup-facebook-coca-cola-or-merck alt=Thinking about trading options or stock in Apple, Citigroup, Facebook, Coca-Cola, or Merck?>Full story available on Benzinga.com</a></p> AAPL Banking/Financial Services C FB KO MRK Opinion Press Releases AAPL US0378331005 C US1729674242 KO US1912161007 MRK US58933Y1055 FB Opinion Press Releases Benzinga Wed, 18 Sep 2019 13:31:00 +0000 PRNewswire 14450889 at https://www.benzinga.com Thinking about buying stock in Aurora Cannabis, DavidsTea, NewLink Genetics, SINTX Technologies, or Spi Energy? https://www.benzinga.com/pressreleases/19/09/n14450888/thinking-about-buying-stock-in-aurora-cannabis-davidstea-newlink-genetics-sintx-technologies-or-sp <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 18, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, DTEA, NLNK, SINT, and SPI.</p> <p xmlns="http://www.w3.org/1999/xhtml">To see how InvestorsObserver&#39;s proprietary scoring system rates these stocks, view the InvestorsObserver&#39;s PriceWatch Alert by selecting the corresponding link.</p> <ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml">ACB: <a xmlns="http://www.w3.org/1999/xhtml" ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/19/09/n14450888/thinking-about-buying-stock-in-aurora-cannabis-davidstea-newlink-genetics-sintx-technologies-or-sp alt=Thinking about buying stock in Aurora Cannabis, DavidsTea, NewLink Genetics, SINTX Technologies, or Spi Energy?>Full story available on Benzinga.com</a></p> ACB Banking/Financial Services DTEA NLNK SINT SPI Opinion Press Releases SPI NLNK DTEA ACB SINT Opinion Press Releases Benzinga Wed, 18 Sep 2019 13:31:00 +0000 PRNewswire 14450888 at https://www.benzinga.com Biotech Companies Endeavor to Address Global Health Issues https://www.benzinga.com/pressreleases/19/09/n14450421/biotech-companies-endeavor-to-address-global-health-issues <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 18, 2019</span> /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report that between 1950 and 2017, there were a total of 359 new diseases and injuries added to the fatal and non-fatal list of conditions. Some of the most common cases include cancer, heart conditions, stroke, respiratory infections, lung diseases, Alzheimer&#39;s, diabetes, and kidney diseases. While some of these conditions are unpreventable, conditions such as cancer and heart issues can be resolved or their spread slowed with innovative treatment and medicine. For instance, patients suffering from cancer typically undergo therapies such as chemotherapy or radiotherapy. Chemotherapy and radiotherapy are two of the most common cancer treatments and are aimed towards prolonging life expectancy, controlling or eradicating malignant cells. And despite its effectiveness, biotechnology companies are continuing to develop new and innovative treatments such as targeted therapies or personalized treatments. Nonetheless, while biotechnology companies are progressing within the industry, each year more and more cases of medical conditions are emerging throughout the world. However, some regions tend to have a more developed healthcare system and can immediately address the needs of their patients. On the other hand, underdeveloped regions typically lack adequate access to proper healthcare, which ultimately results in a large number of fatalities and untreated people. The IHME said in 2017 that regions such as <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Canada</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Japan</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Australia</span>, and western <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Europe</span> had the highest life expectancies. Meanwhile, the central and southern regions in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Africa</span> had the lowest life expectancies. And despite the disparities between the developed and underdeveloped regions, biotechnology companies are slowly moving towards addressing the overall global matter. According to data compiled by Global Market Insights, the global biotechnology market was valued at <span xmlns="http://www.w3.org/1999/xhtml" class="xn-money">USD 399.4 Billion</span> in 2017 and is expected to witness a CAGR of 9.9% from 2018 to 2024. Pressure BioSciences, Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PBIO#OTC" rel="nofollow">PBIO</a>), Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE" rel="nofollow">MRK</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE" rel="nofollow">PFE</a>), GlaxoSmithKline plc (NYSE; GSK), AstraZeneca PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NYSE" rel="nofollow">AZN</a>) </p> <p xmlns="http://www.w3.org/1999/xhtml">Customarily, most cancer patients receive similar treatment depending on their specific type of cancer and the stage progression. However, researchers began to notice that treatments were more effective for some people, while others received experienced little to no response. As such, researchers realized that genetics differences in each patient can influence how they respond to the treatment. For instance, a patient who can process medicine much faster than others would likely require a higher dose of medicine for it to be effective. Moreover, some patients experience severe side effects from specific cancer drugs, making the process unbearable. And in certain instances, doctors will either prescribe an additional medicine or lower the dosage to reduce the painful side effects. Overall, the evolution of personalized treatments has completely reshaped how medical practitioners approach cancer therapy. Notably, researchers have begun to collect tissue samples in order to search for and better understand potential cancer biomarkers. Specifically, formalin-fixed paraffin-embedded (FFPE) and fresh frozen biopsy tissue samples have become widely practiced methods in clinical preservation. Generally, researchers use these tissues to search for specific proteins which can then be used as a diagnosis to indicate which cancer drugs would be the most effective, according to Biochain. Furthermore, biotechnology researchers can accelerate discoveries of new therapies and drugs that can be used towards curing or slowing cancers. &#34;We have yet to realize the full potential of precision medicine, but we are making significant headway,&#34; said <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Eva Kiesler</span>, former Senior Science Editor at Memorial Sloan-Kettering Cancer Center, and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Meredith Begley</span>, Health and Medical writer at Memorial Sloan-Kettering Cancer Center. &#34;Options for many people with cancer have dramatically improved through targeted therapies that reverse the effects of specific gene mutations in their tumor cells.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">Pressure BioSciences, Inc.</b> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/PBIO#OTCQB" rel="nofollow">PBIO</a>) announced last week, &#34;the publication of two scientific journal articles, led by independent teams of  scientists in <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">China</span> and <span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Australia</span>, reporting excellent results with PBI&#39;s Pressure Cycling Technology (&#34;PCT&#34;) platform in processing preserved formalin-fixed paraffin-embedded (&#34;FFPE&#34;) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers and potentially for use in clinical diagnostics based upon these markers.  The Chinese team from Westlake University (<span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">Hangzhou, China</span>) purchased their first two PCT platforms in 2017 and subsequently purchased four additional PCT systems.  The Australian Proteome of Human Cancer (&#34;ProCan&#34;) team bought their first PCT system in 2016 and have subsequently added five more PCT platforms.</p> <p xmlns="http://www.w3.org/1999/xhtml">FFPE preserved tissue samples are an invaluable resource for retrospective studies of disease progression and response to therapy, because the disease outcome associated with the tissue and patient&#39;s treatment history are known. Effective studies on these sample sets can accelerate discoveries of new therapies, drugs, and preventive strategies. FFPE has been long-established as the most common technique worldwide for the preservation of tissues for later study.  Archival repositories exist that contain a total of millions to a billion or more FFPE tissue samples.  However, the analysis of FFPE samples has historically been problematic. FFPE preservation techniques were designed for permanence and stability – hence it is challenging to reverse this fixation and to liberate and extract the important biomolecules relevant as cancer biomarkers.  Significantly, both publications cited here, together with other publications (See PBI Website), now report excellent results using the PCT sample preparation platform for comprehensive and reliable extraction and presentation of important proteins for analysis, from both FFPE and fresh frozen tissue samples.</p> <p xmlns="http://www.w3.org/1999/xhtml">Mr. <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Richard T. Schumacher</span>, President and CEO of Pressure BioSciences, commented: &#39;It is estimated (Nature volume 448, pages 959–962, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">23 August 2007</span>) that well over one billion archival FFPE tissue samples exist in pathology and other laboratories worldwide. We believe there are millions of new FFPE tissue samples processed and stored each year. These samples offer the promise of unveiling invaluable information that can lead to the development of new treatments, cures, and preventive measures for cancer and many other diseases. However, up to now, it has been very difficult to extract this information from biomolecules in FFPE samples.&#39;</p> <p xmlns="http://www.w3.org/1999/xhtml">Ms. <span xmlns="http://www.w3.org/1999/xhtml" class="xn-person">Roxana McCloskey</span>, Director of Marketing and Sales at PBI, said: &#39;We believe that ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14450421/biotech-companies-endeavor-to-address-global-health-issues alt=Biotech Companies Endeavor to Address Global Health Issues>Full story available on Benzinga.com</a></p> AZN MRK PBIO PFE Opinion Press Releases PBIO US74112E1091 AZN US0463531089 MRK US58933Y1055 PFE US7170811035 Opinion Press Releases Benzinga Wed, 18 Sep 2019 13:00:00 +0000 PRNewswire 14450421 at https://www.benzinga.com Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips? https://www.benzinga.com/pressreleases/19/09/n14443328/thinking-about-buying-stock-in-aclaris-therapeutics-alder-biopharmaceuticals-capricor-therapeutics <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 17, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACRS, ALDR, CAPR, CGC, and COP.</p> <p xmlns="http://www.w3.org/1999/xhtml">To see how InvestorsObserver&#39;s proprietary scoring system rates these stocks, view the InvestorsObserver&#39;s PriceWatch Alert by selecting the corresponding link.</p> <ul xmlns="http://www.w3.org/1999/xhtml" type="disc"> <li xmlns="http://www.w3.org/1999/xhtml">ACRS: <a xmlns="http://www.w3.org/1999/xhtml" ...</li></ul><p><a href=https://www.benzinga.com/pressreleases/19/09/n14443328/thinking-about-buying-stock-in-aclaris-therapeutics-alder-biopharmaceuticals-capricor-therapeutics alt=Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips?>Full story available on Benzinga.com</a></p> ACRS ALDR Banking/Financial Services CAPR CGC COP Small Cap Opinion Press Releases COP US20825C1045 CGC ALDR CAPR ACRS Small Cap Opinion Press Releases Benzinga Tue, 17 Sep 2019 13:31:00 +0000 PRNewswire 14443328 at https://www.benzinga.com Thinking about trading options or stock in Alibaba, BP, DISH Network, Visa, or Exxon Mobil? https://www.benzinga.com/pressreleases/19/09/n14443329/thinking-about-trading-options-or-stock-in-alibaba-bp-dish-network-visa-or-exxon-mobil <p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="xn-location">NEW YORK</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="xn-chron">Sept. 17, 2019</span> /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, BP, DISH, V, and XOM.</p> <p xmlns="http://www.w3.org/1999/xhtml">Click a link below then choose between in-depth options trade idea report or a stock score report.</p> <p xmlns="http://www.w3.org/1999/xhtml">Options Report – Ideal trade ideas on up to seven different options ...</p><p><a href=https://www.benzinga.com/pressreleases/19/09/n14443329/thinking-about-trading-options-or-stock-in-alibaba-bp-dish-network-visa-or-exxon-mobil alt=Thinking about trading options or stock in Alibaba, BP, DISH Network, Visa, or Exxon Mobil?>Full story available on Benzinga.com</a></p> BABA Banking/Financial Services BP DISH V XOM Opinion Press Releases DISH US25470M1099 BP US0556221044 V US92826C8394 XOM US30231G1022 BABA Opinion Press Releases Benzinga Tue, 17 Sep 2019 13:31:00 +0000 PRNewswire 14443329 at https://www.benzinga.com